Xiapex(R) Gets Recommendation to be Made Available on National Health Service in England

STOCKHOLM, June 30, 2017 -- (Healthcare Sales & Marketing Network) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that for the first time people in England with the disabling hand condition Dupuytren's disease will have access to Xiapex®... Biopharmaceuticals, Reimbursement Swedish Orphan Biovitrum, Sobi , Xiapex, Dupuytren's disease

Source: HSMN NewsFeed - June 30, 2017 Category: Pharmaceuticals Source Type: news